Content and sentiment analysis of gabapentinoid-related tweets: An infodemiology study.
gabapentin
gabapentinoids
infodemiology
pregabalin
tweets
Journal
Drug and alcohol review
ISSN: 1465-3362
Titre abrégé: Drug Alcohol Rev
Pays: Australia
ID NLM: 9015440
Informations de publication
Date de publication:
20 Dec 2022
20 Dec 2022
Historique:
revised:
22
11
2022
received:
28
09
2022
accepted:
30
11
2022
entrez:
20
12
2022
pubmed:
21
12
2022
medline:
21
12
2022
Statut:
aheadofprint
Résumé
The increasing number of gabapentinoid (pregabalin and gabapentin) harms, including deaths observed across countries is concerning to health-care professionals and policy makers. However, it is unclear if the public shares these concerns. This study aimed to describe posts related to gabapentinoids, conduct a content analysis to identify common themes and describe adverse events or symptoms. Keywords of 'pregabalin' or 'Lyrica' or 'gabapentin' or 'Neurontin' were used to search for related tweets posted by people in the community between 8 March and 7 May 2021. Eligible tweets included a keyword in the post. We extracted de-identified data which included descriptive data of the total number of posts over time; and data on individual tweets including date, number of re-tweets and post content. Data were exported separately for pregabalin- and gabapentin-related tweets. A 20% random sample was used for the thematic analysis. There were 2931 pregabalin-related tweets and 2736 gabapentin-related tweets. Thematic analysis revealed three themes (sharing positive experiences and benefits of taking gabapentinoids, people voicing their negative experiences, and people seeking opinions and sharing information). Positive experiences of gabapentinoids were related to sharing stories and giving advice. This was contrasted to negative experiences including ineffectiveness, withdrawals, side effects and frustration related to cost and insurance coverage. Brain fog was the most common adverse symptom reported. Gabapentinoid-related deaths were only mentioned in three tweets. The increasing public health concern of gabapentinoid-related deaths was not translated to Twitter discussions.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2022 The Authors. Drug and Alcohol Review published by John Wiley & Sons Australia, Ltd on behalf of Australasian Professional Society on Alcohol and other Drugs.
Références
Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49:661-9.
Mathieson S, Valenti L, Maher CG, Britt H, Li Q, McLachlan AJ, et al. Worsening trends in analgesics recommended for spinal pain in primary care. Eur Spine J. 2018;27:1136-45.
Pfizer Inc. Lyrica® prescribing information. 2011. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021446s026,022488s005lbl.pdf. Accessed 2 December 2021.
Upjohn Canada ULC. Product monograph: Lyrica®. 2020. Available from: https://www.pfizer.ca/sites/default/files/202005/Lyrica_PM_E_237599_2020.05.11.pdf. Accessed 2 December 2021.
Mathieson S, Lin C-WC, Underwood M, Eldabe S. Pregabalin and gabapentin for pain. BMJ. 2020;369:m1315.
Johansen ME. Gabapentinoid use in the United States 2002 through 2015. JAMA Intern Med. 2018;178:292-4.
Kwok H, Khuu W, Fernandes K, Martins D, Tadrous M, Singh S, et al. Impact of unrestricted access to pregabalin on the use of opioids and other CNS-active medications: a cross-sectional time series analysis. Pain Med. 2017;18:1019-26.
Torrance N, Veluchamy A, Zhou Y, Fletcher EH, Moir E, Hebert HL, et al. Trends in gabapentinoid prescribing, co-prescribing of opioids and benzodiazepines, and associated deaths in Scotland. Br J Anaesth. 2020;125:159-67.
Ruscitto A, Smith BH, Guthrie B. Changes in opioid and other analgesic use 1995-2010: repeated cross-sectional analysis of dispensed prescribing for a large geographical population in Scotland. Eur J Pain. 2015;19:59-66.
Montastruc F, Loo SY, Renoux C. Trends in first gabapentin and pregabalin prescriptions in primary care in the United Kingdom, 1993-2017. JAMA. 2018;320:2149-50.
Baftiu A, Johannessen Landmark C, Rusten IR, Feet SA, Johannessen SI, Larsson PG. Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders - a pharmacoepidemiological study and clinical implications. Eur J Clin Pharmacol. 2016;72:1245-54.
Schaffer AL, Busingye D, Chidwick K, Brett J, Blogg S. Pregabalin prescribing patterns in Australian general practice, 2012 to 2018. BJGP Open. 2021;5:bjgpopen20X101120.
Pharmaceutics Benefits Scheme. Drug utilisation sub-committee (DUSC); Opioid analgesics. 2020. Available from: https://www.pbs.gov.au/info/industry/listing/participants/public-release-docs/2020-2002/opioid-analgesics. Accessed 2 December 2021.
Iacobucci G. UK government to reclassify pregabalin and gabapentin after rise in deaths. BMJ. 2017;358:j4441.
Peckham AM, Ananickal MJ, Sclar DA. Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance. Risk Manag Healthc Policy. 2018;11:109-16.
Substance Abuse and Mental Health Services Administration. Impact of the DSM-IV to DSM-5 changes on the National Survey on Drug Use and Health. Chapter 2. Substance use disorders. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2016. Available from: https://www.ncbi.nlm.nih.gov/books/NBK519702/. Accessed 2 December 2021
Cairns R, Schaffer AL, Ryan N, Pearson S-A, Buckley NA. Rising pregabalin use and misuse in Australia: trends in utilization and intentional poisonings. Addiction. 2019;114:1026-34.
Pomputius A. Can you hear me now? Social listening as a strategy for understanding user needs. Med Ref Serv Q. 2019;38:181-6.
Eysenbach G. Infodemiology: the epidemiology of (mis)information. Am J Med. 2002;113:763-5.
Pappa D, Stergioulas LK. Harnessing social media data for pharmacovigilance: a review of current state of the art, challenges and future directions. Int J Data Sci Anal. 2019;8:113-35.
Gohil S, Vuik S, Darzi A. Sentiment analysis of health care tweets: review of the methods used. JMIR Public Health Surveill. 2018;4:e43.
Schifano F, D'Offizi S, Piccione M, Corazza O, Deluca P, Davey Z, et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom. 2011;80:118-22.
O'Connor K, Pimpalkhute P, Nikfarjam A, Ginn R, Smith KL, Gonzalez G. Pharmacovigilance on twitter? Mining tweets for adverse drug reactions. AMIA Annu Symp Proc. 2014;2014:924-33.
Sloane R, Osanlou O, Lewis D, Bollegala D, Maskell S, Pirmohamed M. Social media and pharmacovigilance: a review of the opportunities and challenges. Br J Clin Pharmacol. 2015;80:910-20.
Brand24. Privacy policy Brand24 Global Inc. 2018. Available from: https://brand24.com/privacy-policy/. Accessed 2 December 2021.
Spencer L, Ritchie J, Lewis J, Dillon L, National Centre for Social Research. Quality in qualitive evaluation: a framework for assessing research evidence. United Kingdom: Government Chief Social Researcher's Office; 2003.
Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77-101.
O'Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med. 2014;89:1245-51.
World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD-11) 2020. Available from: https://icd.who.int/browse11/l-m/en. Accessed 2 December 2021.
Berkovic D, Ackerman IN, Briggs AM, Ayton D. Tweets by people with arthritis during the COVID-19 pandemic: content and sentiment analysis. J Med Internet Res. 2020;22:e24550.
Bacsu JD, O'Connell ME, Cammer A, Azizi M, Grewal K, Poole L, et al. Using twitter to understand the COVID-19 experiences of people with dementia: infodemiology study. J Med Internet Res. 2021;23:e26254.
Workewych AM, Ciuffetelli Muzzi M, Jing R, Zhang S, Topolovec-Vranic J, Cusimano MD, et al. Twitter and traumatic brain injury: a content and sentiment analysis of tweets pertaining to sport-related brain injury. SAGE Open Med. 2017;5:2050312117720057.
McCausland K, Maycock B, Leaver T, Wolf K, Freeman B, Jancey J. E-cigarette advocates on twitter: content analysis of vaping-related tweets. JMIR Public Health Surveill. 2020;6:e17543.
Waring ME, Baker K, Peluso A, May CN, Pagoto SL. Content analysis of Twitter chatter about indoor tanning. Transl Behav Med. 2019;9:41-7.
Tofighi B, El Shahawy O, Segoshi A, Moreno KP, Badiei B, Sarker A, et al. Assessing perceptions about medications for opioid use disorder and naloxone on Twitter. J Addict Dis. 2021;39:37-45.
World Health Organization. What is Pharmacovigilance? 2021. Available from: https://www.who.int/teams/regulation-prequalification/pharmacovigilance.
O'Hagan ET, Traeger AC, Bunzli S, Leake HB, Schabrun SM, Wand BM, et al. What do people post on social media relative to low back pain? A content analysis of Australian data. Musculoskelet Sci Pract. 2021;54:102402.
Therapeutic Goods Administration. Pregabalin and gabapentin; safety advisory - enhanced warnings relating to abuse and dependence. 2021. Available from: https://www.tga.gov.au/node/936282. Accessed 2 December 2021.
Tambon M, Ponté C, Jouanjus E, Fouilhé N, Micallef J, Lapeyre-Mestre M, et al. Gabapentinoid abuse in France: evidence on health consequences and new points of vigilance. Front Psych. 2021;12:639780.
Ibiloye EA, Barner JC, Lawson KA. Prevalence of and factors associated with gabapentinoid use and misuse among Texas Medicaid recipients. Clin Drug Investig. 2021;41:245-53.
Goins A, Patel K, Alles SRA. The gabapentinoid drugs and their abuse potential. Pharmacol Ther. 2021;227:107926.
Fonseca F, Lenahan W, Dart RC, Papaseit E, Dargan PI, Wood DM, et al. Non-medical use of prescription gabapentinoids (gabapentin and pregabalin) in five European countries. Front Psych. 2021;12:676224.
Grosshans M, Lemenager T, Vollmert C, Kaemmerer N, Schreiner R, Mutschler J, et al. Pregabalin abuse among opiate addicted patients. Eur J Clin Pharmacol. 2013;69:2021-5.
Nahar LK, Murphy KG, Paterson S. Misuse and mortality related to gabapentin and pregabalin are being under-estimated: a two-year post-mortem population study. J Anal Toxicol. 2019;43:564-70.
Schwan S, Sundström A, Stjernberg E, Hallberg E, Hallberg P. A signal for an abuse liability for pregabalin-results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol. 2010;66:947-53.
Pfizer Australia. Australian product information - Lyrica® (pregabalin). 2013. Available from: https://www.pfizermedicalinformation.com.au/en-au/lyrica. Accessed 2 December 2021.
Pfizer Australia. Australian product information - Neurontin® (gabapentin). 2018. Available from: https://www.pfizermedicalinformation.com.au/en-au/neurontin. Accessed 2 December 2021.
Bulter J, Fugh-Berman A. Patient influencers paid by pharmaceutical companies should be required to disclose industry ties. Health Affairs Blog. 2020. Available from: https://www.healthaffairs.org/do/10.1377/hblog20200109.20985594/full/. Accessed 2 December 2021.
Kim JY, Abdi S, Huh B, Kim K-H. Mirogabalin: could it be the next generation gabapentin or pregabalin? Korean J Pain. 2021;34:4-18.
Kato J, Baba M, Kuroha M, Kakehi Y, Murayama E, Wasaki Y, et al. Safety and efficacy of mirogabalin for peripheral neuropathic pain: pooled analysis of two pivotal phase III studies. Clin Ther. 2021;43:822-35.
Kato J, Matsui N, Kakehi Y, Murayama E, Ohwada S. Long-term safety and efficacy of mirogabalin in Asian patients with postherpetic neuralgia: results from an open-label extension of a multicenter randomized, double-blind, placebo-controlled trial. Medicine (Baltimore). 2020;99:e21976.
Merante D. The mirogabalin ALDAY phase 3 program in pain associated with fibromyalgia: the lessons learned. Curr Med Res Opin. 2020;36:661-6.